We are live on ! Find out more
VNRX icon

VolitionRx Ltd

16 hedge funds and large institutions have $23.9M invested in VolitionRx Ltd in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

147% more capital invested

Capital invested by funds: $9.66M → $23.9M (+$14.2M)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

7% more funds holding

Funds holding: 1516 (+1)

0.3% more ownership

Funds ownership: 0.66%0.95% (+0.3%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.43%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
5
Increased
6
Reduced
1
Closed
4
Calls
Puts
Net Calls
Net Calls Change

VNRX Hedge Fund Activity: Q3 2016 in Review

16 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VolitionRx Ltd (VNRX) for Q3 2016, worth a combined $23.9M — up 147% from $9.66M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VNRX positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Lagoda Investment Management, adding an estimated $5.07M. The largest seller was Goldman Sachs, exiting entirely with an estimated $61K sold.

  • 16 institutional investors held VolitionRx Ltd (VNRX) as of Q3 2016, up from 15 in Q2 2016.
  • Funds reported $23.9M of VolitionRx Ltd stock for Q3 2016, up 147% quarter-over-quarter.
  • 5 funds opened new VolitionRx Ltd positions in Q3 2016 and 4 closed out, a net change of +1 holder.
  • The largest VolitionRx Ltd buyer in Q3 2016 was Lagoda Investment Management, an estimated $5.07M added.
  • The largest VolitionRx Ltd seller in Q3 2016 was Goldman Sachs, an estimated $61K sold.

Based on aggregated 13F filings for Q3 2016.